Analytical Data
-
基因名
AGA2
- Application
-
别名
AGA2；A-agglutinin-binding subunit
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P32781
-
表达区间
19-87aa
-
氨基酸序列
QELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF
-
分子量
9.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AGA2, or Alpha-Galactosidase A2, is an enzyme that plays a critical role in the metabolism of glycosphingolipids and is primarily associated with Fabry disease, a genetic disorder caused by a deficiency in Alpha-Galactosidase A. The recombinant production of AGA2 protein has garnered significant interest in biomedical research due to its potential in gene therapy and enzyme replacement therapy for Fabry disease. Recent advancements in protein engineering, expression systems, and purification techniques have enabled more efficient production of recombinant AGA2, allowing researchers to study its biochemical properties and therapeutic potential. Understanding AGA2’s structure-function relationship is crucial not only for addressing Fabry disease but also for exploring its broader implications in lysosomal storage disorders. Moreover, recombinant AGA2 can serve as a valuable tool for the development of diagnostic assays and therapeutic agents, enhancing our ability to manage and potentially cure such metabolic diseases. Ongoing studies focus on optimizing AGA2’s expression levels, improving its stability, and understanding how post-translational modifications influence its activity and therapeutic efficacy. This research is vital for paving the way toward innovative treatments that can alleviate the symptoms and improve the quality of life for individuals affected by Fabry disease.
